BIAF · XBRL financial data

bioAffinity Technologies financial statements, every fiscal year

The same tables from 4 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (BIAF's year ends in late December)

In thousands of dollars	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025†Dec 31, 2025
Revenue	6,900	7,900	—	—
Revenue from contracts with customers	5	2,532	9,362	6,162
Cost of revenue	0	—	—	—
Gross profit	4	—	—	—
Research and development	1,143	1,468	1,461	1,383
Selling, general and administrative	2,727	6,791	9,943	9,914
Total operating expenses	4,015	10,506	18,315	16,734
Operating income (loss)	(4,011)	(7,973)	(8,953)	(10,573)
Interest income	47	122	18	23
Interest expense	2,533	37	92	44
Income tax expense (benefit)	2	21	12	44
Net income (loss)	(8,154)	(7,937)	(9,040)	(14,910)
Earnings per share, basic USD per share	(1.81)	(0.91)	(0.75)	(8.66)
Earnings per share, diluted USD per share	(1.81)	(0.91)	(0.75)	(8.66)
Weighted average shares, basic thousands of shares	4,499	8,748	12,125	1,721
Weighted average shares, diluted thousands of shares	4,499	8,748	12,125	1,721

† Share count changed about 1/4 in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (BIAF's year ends in late December)

In thousands of dollars	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025†Dec 31, 2025
Cash and cash equivalents	11,414	2,822	1,105	6,450
Inventory	6	18	28	54
Prepaid and other current assets	532	321	423	520
Total current assets	11,962	3,973	2,695	7,565
Property and equipment, net	214	459	375	266
Right-of-use asset	—	370	463	334
Goodwill	—	1,404	1,404	1,404
Total assets	12,182	8,222	6,514	10,961
Accounts payable	345	605	987	762
Accrued liabilities	542	1,150	1,399	1,718
Total current liabilities	1,139	2,248	3,105	2,906
Lease liability, non-current	—	283	342	203
Total liabilities	1,139	3,366	3,912	3,683
Accumulated deficit	(36,667)	(44,604)	(53,644)	(68,554)
Total stockholders' equity	11,043	4,855	2,602	7,278
Total liabilities and equity	12,182	8,222	6,514	10,961
Common shares outstanding (cover page) thousands of shares	8,463	11,514	18,256	4,499

† Share count changed about 1/4 in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (BIAF's year ends in late December)

In thousands of dollars	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025†Dec 31, 2025
Net income (loss)	(8,154)	(7,937)	(9,040)	(14,910)
Stock-based compensation	249	749	990	671
Net cash from operating activities	(4,071)	(6,038)	(7,265)	(9,329)
Purchases of property and equipment	220	23	79	61
Net cash from investing activities	(220)	(2,209)	(79)	(61)
Net cash from financing activities	14,344	(345)	5,628	14,734
Net change in cash	10,053	(8,592)	(1,716)	5,344

† Share count changed about 1/4 in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 8731 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 8731 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
bioAffinity Technologies	2,430	1,511	(3,201)*	8.1M	0.8 quarters	Q2 FY26 10-QJun 30, 2026
IB Acquisition	30	not reported	(474)*	5.0M	0.1 quarters	Q3 FY26 10-QJun 30, 2026
OneMedNet	358	292	(1,875)*	59.3M	0.2 quarters	Q2 FY26 10-QJun 30, 2026
20/20 Biolabs	4,546	731	(605)*	12.8M	7.5 quarters	Q2 FY26 10-QJun 30, 2026
Inotiv	15,180	117,652	(1,070)*	34.9M	14.2 quarters	Q2 FY26 10-QMar 31, 2026

Not investment advice. Not affiliated with the U.S. SEC.